Tanigawa N, Lu C, Mitsui T, Miura S
Second Department of Surgery, Fukui Medical School, Japan.
Hepatology. 1997 Nov;26(5):1216-23. doi: 10.1053/jhep.1997.v26.pm0009362365.
Angiogenesis is crucial for tumor growth and metastasis. Hepatocellular carcinoma (HCC) is a typical hypervascular tumor. However, the relationship between tumor vascularity and the outcome of patients with HCC has not been evaluated. To clarify whether tumor angiogenesis is related to the prognosis of patients, immunohistochemical staining, using anti-von Willebrand factor (vWF) and anti-CD34, was applied in resected specimens from 43 cases of HCC. In nonmalignant tissue, staining was confined to vessels in the portal tract and to a few periportal sinusoids with both of the endothelial markers applied. In tumor tissue, however, sinusoid-like vessels reacted intensively with anti-CD34 but not with anti-vWF. The intratumor microvessel density (MVD) highlighted by anti-CD34 was 297 +/- 88 (per 0.74 mm2), which was significantly higher than that highlighted by anti-vWF (4 +/- 7). When only the MVD highlighted by anti-CD34 was analyzed, tumor diameter larger than 2 cm, poor differentiation (Edmondson's II to IV), and portal invasion were significantly related to the subgroup with MVD > or = 290. Overall survival curves of patients with MVD < 290 were better, and these patients were more likely to remain tumor free. Cox hazards model revealed intratumor MVD and Edmondson's grade to be independent prognostic factors for the overall survival of patients. These results demonstrated for the first time that tumor angiogenesis assessed by anti-CD34 was correlated with the outcome of patients with HCC, suggesting a potential role for anti-CD34 in the diagnosis and treatment of HCC.
血管生成对于肿瘤的生长和转移至关重要。肝细胞癌(HCC)是一种典型的富血管肿瘤。然而,肿瘤血管生成与HCC患者预后之间的关系尚未得到评估。为了阐明肿瘤血管生成是否与患者预后相关,对43例HCC切除标本应用抗血管性血友病因子(vWF)和抗CD34进行免疫组化染色。在非恶性组织中,两种内皮标志物染色均局限于门脉区血管和少数门脉周围的肝血窦。然而,在肿瘤组织中,类肝血窦样血管对抗CD34反应强烈,但对抗vWF无反应。抗CD34突出显示的瘤内微血管密度(MVD)为297±88(每0.74mm²),显著高于抗vWF突出显示的MVD(4±7)。仅分析抗CD34突出显示的MVD时,肿瘤直径大于2cm、低分化(Edmondson II至IV级)和门脉侵犯与MVD≥290的亚组显著相关。MVD<290患者的总生存曲线更好,且这些患者更可能无瘤生存。Cox风险模型显示瘤内MVD和Edmondson分级是患者总生存的独立预后因素。这些结果首次证明,抗CD34评估的肿瘤血管生成与HCC患者的预后相关,提示抗CD34在HCC诊断和治疗中具有潜在作用。